<DOC>
	<DOC>NCT02126306</DOC>
	<brief_summary>Oral administration of betaglucosylceramide was shown effective in reducing inflammation in animal models and was found safe in humans.</brief_summary>
	<brief_title>Beta Glucosylceramide for Treatment of NASH</brief_title>
	<detailed_description>Patients with NASH to receive the treatment versus placebo for 40 weeks followed by a liver biopsy.</detailed_description>
	<criteria>Biopsy proven NASH Other therapies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2006</verification_date>
</DOC>